Replies to post #212593 on Biotech Values

[DewDiligence]

Re: Keytruda ‘failure’ in second-line H&N cancer:

Doubt that AA will be rescinded based on OS HR=0.82 w 95% CI [0.67-1.01]. Not gonna happen with current FDA, IMO. $MRK

— Roy Friedman (@DewDiligence) July 24, 2017

https://twitter.com/DewDiligence/status/889600834648125440